News
Newton Biocapital is proud to announce that it has been certified as a part of “New Drug Discovery Venture Ecosystem Strengthening Project” by AMED (Japan Agency for Medical Research and Development).
According to the announcement by AMED on its website, 24 venture capital firms applied for the accreditation, from which only 8 were accepted. Newton Biocapital is the first and only EURO-Japan fund to be nominated.
This is a new initiative implemented by the Japanese Ministry of Economy, Trade and Industry (METI) and executed by AMED. Under this initiative, AMED certified venture capital funds that are investing in early stage (from preclinical to phase 2 clinical trials) drug discovery ventures with global reach of network as an attempt to strengthen new drug discovery venture ecosystem to promote innovation originating from Japan.
This AMED certification is a symbol of trust, expertise and proven track record of Newton Biocapital for the strengthening of the new drug discovery venture ecosystem in Japan. Newton Biocapital’s unique team of European and Japanese experts is determined to assist Japanese start-ups engaged in new drug discovery on their path to success.
https://www.amed.go.jp/en/abou...